Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cambrex Corp (NYSE:CBM)

50.70
Delayed Data
As of 4:02pm ET
 +0.55 / +1.10%
Today’s Change
29.50
Today|||52-Week Range
59.41
+7.67%
Year-to-Date
Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug
10:09am / Zacks.com - Paid Partner Content
Zacks.com featured highlights: Alliance Resource Partners, EnerSys, Cambrex and Child...
Nov 29 / Zacks.com - Paid Partner Content
Merck KGaA (MKGAF) Expands Distribution Deal with Roche
9:29am / Zacks.com - Paid Partner Content
Zacks.com featured highlights: Edgewell Personal Care, Cambrex, Humana, Research Fron...
Nov 29 / Zacks.com - Paid Partner Content
5 Stocks with Solid Net Profit Margin to Bet On
8:06am / Zacks.com - Paid Partner Content
BioDelivery Sciences: Can Bunvail and Belbuca's Sales Improve?
Nov 28 / Zacks.com - Paid Partner Content
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.
Dec 01 / Zacks.com - Paid Partner Content
Bet on These 4 Top Stocks with Upgraded Broker Ratings
Nov 28 / Zacks.com - Paid Partner Content
Ultragenyx (RARE) Reports Positive Phase II Study on UX007
Dec 01 / Zacks.com - Paid Partner Content
Glaxo (GSK) Files Regulatory Application for Shingrix in EU
Nov 28 / Zacks.com - Paid Partner Content
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
Dec 01 / Zacks.com - Paid Partner Content
Bet on Stocks with Rising P/E to Enjoy Growing Gains
Nov 28 / Zacks.com - Paid Partner Content
Achillion, J&J to Initiate Phase IIb Study on HCV Combo
Dec 01 / Zacks.com - Paid Partner Content
Eli Lilly Hits 52-Week Low on Poor Data on Alzheimer's Drug
Nov 25 / Zacks.com - Paid Partner Content
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile
Nov 30 / Zacks.com - Paid Partner Content
Merck's New Drugs, Cost Management to Fuel Growth in 2017
Nov 25 / Zacks.com - Paid Partner Content
Zacks.com featured highlights: Forestar Real Estate Group, McDermott International, C...
Nov 30 / Zacks.com - Paid Partner Content
Why You Shouldn't Bet Against Cambrex (CBM) Stock
Nov 22 / Zacks.com - Paid Partner Content
Mallinckrodt (MNK) Tops Q4 Earnings on Solid Sales Growth
Nov 29 / Zacks.com - Paid Partner Content
Acorda Stops Post-Stroke Development Program on Ampyra
Nov 22 / Zacks.com - Paid Partner Content
Amicus Provides Regulatory Update on Fabry Disease Drug
Nov 29 / Zacks.com - Paid Partner Content
Zacks.com featured highlights: Stamps.com, Cambrex, Gibraltar Industries and FutureFu...
Nov 21 / Zacks.com - Paid Partner Content
7 Stocks Near 52-Week Highs to Buy Right Away
Nov 29 / Zacks.com - Paid Partner Content
Spectrum (SPPI) Gets CRL for Bladder Cancer Drug in U.S.
Nov 21 / Zacks.com - Paid Partner Content